1. Distributions, if any, will be made commencing on June 25, 2017. The estimated net annual distribution is expected to decline over time because a portion of the securities included in the portfolio will be sold to pay for organization costs, creation and development fee and deferred sales charge. Distributions will fluctuate as a result of unitholder redemptions in addition to securities being sold within the portfolio. Distributions are also subject to the ability of issuers to make dividend payments in the future.

2. Estimated Net Annual First Year Distribution per unit is computed by dividing the estimated annual income of the underlying securities less the expense per unit by the number of units outstanding. The estimated net annual distributions for subsequent years are expected to be less than estimated distributions for the first year because a portion of the securities included in the trust portfolio will be sold during the first year to pay for organization costs, the creation and development fee and the deferred sales charge. The actual net annual distributions will vary with changes in the trust’s fees and expenses and income of the underlying securities.

Investors should consider the trust’s investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the trust. Please read the prospectus carefully before you invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

Hennion & Walsh is a member of FINRA/SIPC.

2001 Route 46, Waterview Plaza, Parsippany, NJ 07054  (888) 505-2872  www.smarttrustuit.com

NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE
Sales Charges\(^4\) (based on a $10 public offering price)

<table>
<thead>
<tr>
<th>Standard Accounts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transactional Sales Charge:</td>
</tr>
<tr>
<td>Creation &amp; Development Fee(^3):</td>
</tr>
<tr>
<td>Maximum Sales Charge:</td>
</tr>
</tbody>
</table>

The deferred sales charge is a charge of $0.245 per unit and will be deducted in three monthly installments commencing on November 20, 2017. The initial and deferred sales fees do not apply to fee-based accounts. Please see the prospectus for sales charge details.

Fee/Wrap Accounts

| Creation & Development Fee\(^3\): | $0.05 |
| Maximum Sales Charge: | $0.05 |

\(^4\)Percentages are based on a $10.00 per unit offering price. For unit prices other than $10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

\(^3\)The creation and development fee is a charge of $0.05 per unit collected at the end of the initial offering period. If the price you pay exceeds $10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than $10 per unit, the creation and development fee will exceed 0.50%. In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

Volume Discounts

<table>
<thead>
<tr>
<th>PURCHASE AMOUNT(^3)</th>
<th>SALES CHARGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than $50,000</td>
<td>3.95%</td>
</tr>
<tr>
<td>$50,000 but less than $100,000</td>
<td>3.70%</td>
</tr>
<tr>
<td>$100,000 but less than $250,000</td>
<td>3.45%</td>
</tr>
<tr>
<td>$250,000 but less than $500,000</td>
<td>3.10%</td>
</tr>
<tr>
<td>$500,000 but less than $1,000,000</td>
<td>2.95%</td>
</tr>
<tr>
<td>$1,000,000 or greater</td>
<td>2.45%</td>
</tr>
</tbody>
</table>

\(^3\)The volume discount is also applied on a unit basis utilizing a breakpoint equivalent in the above table of one unit per $10. Please see the trust prospectus for full details. These discounts are only offered during the initial offering period.

Portfolio Holdings as of May 2, 2017:

<table>
<thead>
<tr>
<th>Equity Securities — 100.00%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Care — 100.00%</td>
</tr>
</tbody>
</table>

- **ACADIA Pharmaceuticals Inc.**
- **Puma Biotechnology, Inc.**
- **Agios Pharmaceuticals, Inc.**
- **Acorda Therapeutics, Inc.**
- **FibroGen, Inc.**
- **The Medicines Company**
- **Alnylam Pharmaceuticals, Inc.**
- **Axovant Sciences Ltd.**
- **Spark Therapeutics, Inc.**
- **Alder BioPharmaceuticals, Inc.**
- **Aerie Pharmaceuticals, Inc.**
- **Alexion Pharmaceuticals, Inc.**
- **DBV Technologies S.A.**
- **Pacira Pharmaceuticals, Inc.**
- **Ophthotech Corporation**
- **bluebird bio, Inc.**
- **Ironwood Pharmaceuticals, Inc.**
- **Acceleron Pharma Inc.**
- **GW Pharmaceuticals plc**
- **Vertex Pharmaceuticals Incorporated**
- **Galapagos NV**
- **Valeant Pharmaceuticals International, Inc.**
- **Clovis Oncology, Inc.**
- **Aier Pharmaceticals, Inc.**
- **Agios Pharmaceuticals, Inc.**
- **Aldar BioPharmaceuticals, Inc.**
- **Allexion Pharmaceuticals, Inc.**
- **Alnylam Pharmaceuticals, Inc.**
- **Array BioPharma Inc.**
- **Axovant Sciences Ltd.**
- **bluebird bio, Inc.**
- **Ironwood Pharmaceuticals, Inc.**
- **Acceleron Pharma Inc.**
- **GW Pharmaceuticals plc**
- **Horizon Pharma plc**
- **Incyte Corporation**
- **Ironwood Pharmaceuticals, Inc.**
- **Jazz Pharmaceuticals plc**
- **Kite Pharma, Inc.**
- **Medicines Company**
- **Ophthotech Corporation**
- **Pacira Pharmaceuticals, Inc.**
- **Puma Biotechnology, Inc.**
- **Spark Therapeutics, Inc.**
- **Ultragenyx Pharmaceutical Inc.**
- **Valent Pharmaceuticals International, Inc.**
- **Vertex Pharmaceuticals Incorporated**

Risk Considerations

Unitholders can lose money by investing in this trust. An investment in units of the trust should be made with an understanding of the risks related to the trust, such as the following:

- Security prices will fluctuate. The value of your investment may fall over time.
- The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your units. This may occur at any point in time, including during the initial offering period.
- The issuer of a security may be unwilling or unable to declare dividends in the future or may reduce the level of dividends declared. This may reduce the level of distributions the trust pays which could reduce your income and cause the value of your units to fall.
- The trust invests in securities from the Index selected prior to the date of the trust’s formation. The securities in the trust’s portfolio will not change if the Index components, or their weightings within the Index, change. The performance of the trust may not correspond with the Index for this reason and because the trust incurs a sales charge and expenses.
- The trust is considered to be concentrated in securities issued by companies in the health care sector. Negative developments in this sector will affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include extensive competition, generic drug sales, the loss of patent protection, product liability litigation, increased government regulation, and challenges in obtaining regulatory approval for drugs and therapies.
- The trust may invest in securities of foreign issuers, which may include companies located in emerging markets. These risks may include market and political factors related to the company’s foreign market, international trade conditions, less regulation, smaller or less liquid markets, increased volatility, differing accounting practices and changes in the value of foreign currencies.
- The trust may invest in stocks of small and mid-size companies. These stocks are often more volatile and have lower trading volumes than stocks of larger companies. Small and mid-size companies may have limited products or financial resources, management inexperience and less publicly available information.
- The trust is not actively managed. Except in limited circumstances, the trust will hold, and continue to buy, shares of the same securities even if their market value declines.
- The sponsor may offer successive trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive trusts, if available. There may be tax consequences associated with investing in the trust and rolling over an investment from one trust to the next.